Epigenomics
Founded Year
1998Stage
PIPE - II | IPOAbout Epigenomics
Epigenomics is a molecular diagnostics company focusing on blood-based detection of cancers using its proprietary DNA methylation technology. The company develops and commercializes blood-based diagnostic products across multiple cancer indications with high medical need.
Missing: Epigenomics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Epigenomics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Epigenomics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Epigenomics is included in 3 Expert Collections, including Cancer.
Cancer
3,710 items
Products/services that analyze tumor-derived biomarkers (ctDNA, CTCs, exosomes) in blood/urine/other non-invasive liquid specimens to detect cancer earlier, guide treatment, and monitor progress. *Data fields manually updated as new information becomes available.'
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Medical Devices
295 items
Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA
Epigenomics Patents
Epigenomics has filed 72 patents.
The 3 most popular patent topics include:
- Molecular biology
- Genetics
- DNA
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/8/2018 | 5/31/2022 | Molecular biology, DNA, Genetics, Epigenetics, Transcription factors | Grant |
Application Date | 3/8/2018 |
|---|---|
Grant Date | 5/31/2022 |
Title | |
Related Topics | Molecular biology, DNA, Genetics, Epigenetics, Transcription factors |
Status | Grant |
Latest Epigenomics News
Jan 27, 2023
<table border="0"><tr><td> EQS-Ad-hoc: <a href="/aktien/epigenomics_7-aktie">Epigenomics</a> AG / Key word(s): Personnel<br/> Epigenomics AG: Resignation of the Chairman of the Supervisory Board Heino von Prondzynski <br/><br/> 27-Jan-2023 / 14:16 CET/CEST<br/> Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU)...
Epigenomics Frequently Asked Questions (FAQ)
When was Epigenomics founded?
Epigenomics was founded in 1998.
Where is Epigenomics's headquarters?
Epigenomics's headquarters is located at Geneststrasse 5, Berlin.
What is Epigenomics's latest funding round?
Epigenomics's latest funding round is PIPE - II.
Who are the investors of Epigenomics?
Investors of Epigenomics include Cathay Fortune International, Abingworth, MPM Capital and Deutsche Venture Capital.
Who are Epigenomics's competitors?
Competitors of Epigenomics include EDP Biotech and 2 more.
Compare Epigenomics to Competitors
Geneoscopy is developing next generation diagnostics that leverage the power of stool-derived eukaryotic RNA (seRNA) to better prevent, detect, and guide treatment for gastrointestinal disease.
LungLife AI is focused on the development of the LiquidBiopsy platform, a high-performance rare cell isolation technology for biomedical research and cancer diagnostics. LiquidBiopsy is a key enabling technology to realize the promise of personalized medicine, including the early detection of disease, real-time monitoring of patients, and the selection of individual therapeutic solutions.
PixCell Medical Technologies is a privately held company developing cell-based diagnostics for the point of care (POC), based on its viscoelastic focusing and microfluidics technology. The company's core technology is comprised of an analyzer and a self-contained disposable cartridge. On May 3, 2021, PixCell Medical Technologies was acquired by Soulbrain. The terms of the transaction were not disclosed.
Haemonetics is a medical device company. It had developed the Haemonetics Cell Saver Elite Autotransfusion System.Haemonetics is a global company that markets automated blood processing systems. These systems help increase the safety, quality and availability of the world blood supply by addressing important medical markets: surgical blood salvage, blood component collections and plasma collections.
Truvian Sciences is a healthcare company at the intersection of diagnostics and consumer technology. Its automated benchtop system produces lab-accurate results for a full suite of health tests using a small sample of blood. Powered by patented technologies and intelligent integration, Truvian's system delivers an alternative to off-site labs, providing immediate insights to inform healthcare decisions.
OncoHost combines life-science research and advanced machine learning technology to develop personalized strategies to maximize the success of cancer therapy. Utilizing proprietary proteomic analysis, the company aims to understand patients' unique response to therapy and overcome one of the major obstacles in clinical oncology: resistance to therapy. OncoHost's host response profiling platform, PROphet®, analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient (i.e. the host) in response to a given cancer therapy. This proteomic profile is highly predictive of individual patient outcome, thus enabling personalized treatment planning. PROphet® also identifies potential drug targets, advancing the development of therapeutic strategies, as well as rationally-based combination therapies. The company was founded in 2017 and is based in Binyamina, Israel.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.